RPHPYRO
Disodium tetradecahydrate pyrophosphate
Image for illustration purposes only.
Presentation:Kit containing 5 vials of lyophilized powder for injectable solution. Sterile product, non-pyrogenic and under nitrogen atmosphere for complexation with the radioisotope metastable technetium-99m (99mTc).
Indications:Used mainly in myocardial scintigraphy for the assessment of acute myocardial infarction and the extension of necrosis process. It can be used as an image agent to demonstrate areas of altered osteogenesis. It can also be used as agent to blood pool imaging, ventriculography and
bleed research when administered 20 to 30 minutes after blood labeling.
POSOLOGY AND METHOD OF ADMINISTRATION
Rout of administration: intravenous.
Bone scintigraphy in adults with 70 kg is from 740 MBq (20 mCi) to 1110 MBq (30 mCi).
For myocardial scintigraphy in adults with 70 kg is 740 MBq (15-20 mCi).
Blood pool: in vivo labeling: 555-740 MBq (15-20 mCi) and In vitro: 74-740 MBq (2-20 mCi).
Conditions of storage:
• Pre-labeling: From 2 ºC to 8 ºC, protected from light.
• Post-labeling: room temperature of 15 to 30 ºC, protected from light.
Stability post-labeling: 4 hours in room temperature (15 to 30 ºC)
Product expiration date: 12 months
Number of vials per kit: 5
Registration: MS. 1.7359.0006.001-0
AVAILABLE BY PRESCRIPTION ONLY – RESTRICTED USE TO HOSPITALS.
IF SYMPTOMS PERSIST, A DOCTOR SHOULD BE CONSULTED.
Contraindications, warnings, adverse reactions, drug interactions, precautions and posology: refer to package leaflet.
R2Pharma products are available only by means of medical prescription from a licensed physician.
IF SYMPTOMS PERSIST, A DOCTOR SHOULD BE CONSULTED.
Contraindications, warnings, adverse reactions, drug interactions, precautions and posology: refer to package leaflet.
The content of this page is destined to health professionals.